{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T16:21:13Z","timestamp":1772900473235,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T00:00:00Z","timestamp":1704153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","award":["320.6750"],"award-info":[{"award-number":["320.6750"]}],"id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009399","name":"Peking University Third Hospital","doi-asserted-by":"publisher","award":["BYSYDL2021006"],"award-info":[{"award-number":["BYSYDL2021006"]}],"id":[{"id":"10.13039\/501100009399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00277-023-05597-5","type":"journal-article","created":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T16:03:58Z","timestamp":1704211438000},"page":"2381-2391","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Genetic and prognostic analysis of blastoid and pleomorphic mantle cell lymphoma: a multicenter analysis in China"],"prefix":"10.1007","volume":"103","author":[{"given":"Ping","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo-Zi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Long","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-Tong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cui-Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing-Qing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4958-2489","authenticated-orcid":false,"given":"Hong-Mei","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,2]]},"reference":[{"issue":"6","key":"5597_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66(6):443\u2013459. https:\/\/doi.org\/10.3322\/caac.21357","journal-title":"CA Cancer J Clin"},{"issue":"19","key":"5597_CR2","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O et al (2010) Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116(19):3724\u20133734. https:\/\/doi.org\/10.1182\/blood-2010-05-282632","journal-title":"Blood"},{"issue":"6","key":"5597_CR3","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ajh.25487","volume":"94","author":"P Jain","year":"2019","unstructured":"Jain P, Wang M (2019) Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol 94(6):710\u2013725. https:\/\/doi.org\/10.1002\/ajh.25487","journal-title":"Am J Hematol"},{"issue":"8","key":"5597_CR4","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","volume":"124","author":"A Abrahamsson","year":"2014","unstructured":"Abrahamsson A, Albertsson-Lindblad A, Brown PN, Baumgartner-Wennerholm S, Pedersen LM, D\u2019Amore F et al (2014) Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood 124(8):1288\u20131295. https:\/\/doi.org\/10.1182\/blood-2014-03-559930","journal-title":"Blood"},{"issue":"1","key":"5597_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","volume":"117","author":"P P\u00e9rez-Gal\u00e1n","year":"2011","unstructured":"P\u00e9rez-Gal\u00e1n P, Dreyling M, Wiestner A (2011) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117(1):26\u201338. https:\/\/doi.org\/10.1182\/blood-2010-04-189977","journal-title":"Blood"},{"key":"5597_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_349509","volume":"42","author":"A Kumar","year":"2022","unstructured":"Kumar A, Eyre TA, Lewis KL, Thompson MC, Cheah CY (2022) New directions for mantle cell lymphoma in 2022. Am Soc Clin Oncol Educ Book 42:1\u201315. https:\/\/doi.org\/10.1200\/edbk_349509","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"5597_CR7","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ajh.26523","volume":"97","author":"P Jain","year":"2022","unstructured":"Jain P, Wang ML (2022) Mantle cell lymphoma in 2022-a comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol 97(5):638\u2013656. https:\/\/doi.org\/10.1002\/ajh.26523","journal-title":"Am J Hematol"},{"issue":"26","key":"5597_CR8","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1182\/blood-2017-08-737502","volume":"132","author":"M Dreyling","year":"2018","unstructured":"Dreyling M, Klapper W, Rule S (2018) Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge! Blood 132(26):2722\u20132729. https:\/\/doi.org\/10.1182\/blood-2017-08-737502","journal-title":"Blood"},{"issue":"6","key":"5597_CR9","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1182\/bloodadvances.2019001396","volume":"4","author":"P Jain","year":"2020","unstructured":"Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN et al (2020) Genomic profiles and clinical outcomes of de novo blastoid\/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038\u20131050. https:\/\/doi.org\/10.1182\/bloodadvances.2019001396","journal-title":"Blood Adv"},{"issue":"1","key":"5597_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","volume":"131","author":"M Tiemann","year":"2005","unstructured":"Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A et al (2005) Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 131(1):29\u201338. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05716.x","journal-title":"Br J Haematol"},{"issue":"13","key":"5597_CR11","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1182\/bloodadvances.2019001350","volume":"4","author":"HA Hill","year":"2020","unstructured":"Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S et al (2020) Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv 4(13):2927\u20132938. https:\/\/doi.org\/10.1182\/bloodadvances.2019001350","journal-title":"Blood Adv"},{"issue":"5\u20136","key":"5597_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41417-018-0022-5","volume":"25","author":"P Yang","year":"2018","unstructured":"Yang P, Zhang W, Wang J, Liu Y, An R, Jing H (2018) Genomic landscape and prognostic analysis of mantle cell lymphoma. Cancer Gene Ther 25(5\u20136):129\u2013140. https:\/\/doi.org\/10.1038\/s41417-018-0022-5","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"5597_CR13","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bjh.17419","volume":"195","author":"E Silkenstedt","year":"2021","unstructured":"Silkenstedt E, Linton K, Dreyling M (2021) Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches. Br J Haematol 195(2):162\u2013173. https:\/\/doi.org\/10.1111\/bjh.17419","journal-title":"Br J Haematol"},{"issue":"5","key":"5597_CR14","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.hoc.2020.06.009","volume":"34","author":"P Jain","year":"2020","unstructured":"Jain P, Wang M (2020) Blastoid mantle cell lymphoma. Hematol Oncol Clin North Am 34(5):941\u2013956. https:\/\/doi.org\/10.1016\/j.hoc.2020.06.009","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"5597_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.4081\/aiua.2019.1.49","volume":"91","author":"F Palmisano","year":"2019","unstructured":"Palmisano F, Lorusso V, Spinelli MG, Dell\u2019Orto PG, Montanari E (2019) Blastoid variant of mantle cell lymphoma of the female urethra mimicking a caruncle: a rare but highly aggressive subtype case with literature review. Arch Ital Urol Androl 91(1):49\u201350. https:\/\/doi.org\/10.4081\/aiua.2019.1.49","journal-title":"Arch Ital Urol Androl"},{"issue":"3","key":"5597_CR16","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1111\/bjh.17452","volume":"194","author":"AFP Overweel","year":"2021","unstructured":"Overweel AFP, Budel LM, Sandberg Y (2021) Cutaneous blastoid mantle cell lymphoma. Br J Haematol 194(3):490. https:\/\/doi.org\/10.1111\/bjh.17452","journal-title":"Br J Haematol"},{"issue":"2","key":"5597_CR17","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s12105-021-01391-9","volume":"16","author":"M Georgaki","year":"2022","unstructured":"Georgaki M, Theofilou VI, Pettas E, Piperi E, Stoufi E, Panayiotidis P et al (2022) Blastoid mantle cell lymphoma of the palate: report of a rare aggressive entity and review of the literature. Head Neck Pathol 16(2):631\u2013642. https:\/\/doi.org\/10.1007\/s12105-021-01391-9","journal-title":"Head Neck Pathol"},{"issue":"17","key":"5597_CR18","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","volume":"130","author":"CW Eskelund","year":"2017","unstructured":"Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB et al (2017) TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 130(17):1903\u20131910. https:\/\/doi.org\/10.1182\/blood-2017-04-779736","journal-title":"Blood"},{"issue":"12","key":"5597_CR19","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/leu.2011.162","volume":"25","author":"AM Halld\u00f3rsd\u00f3ttir","year":"2011","unstructured":"Halld\u00f3rsd\u00f3ttir AM, Lundin A, Murray F, Mansouri L, Knuutila S, Sundstr\u00f6m C et al (2011) Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia 25(12):1904\u20131908. https:\/\/doi.org\/10.1038\/leu.2011.162","journal-title":"Leukemia"},{"issue":"1","key":"5597_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/gcc.22123","volume":"53","author":"C Sarkozy","year":"2014","unstructured":"Sarkozy C, Terr\u00e9 C, Jardin F, Radford I, Roche-Lestienne C, Penther D et al (2014) Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. Genes Chromosomes Cancer 53(1):106\u2013116. https:\/\/doi.org\/10.1002\/gcc.22123","journal-title":"Genes Chromosomes Cancer"},{"issue":"11","key":"5597_CR21","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1002\/cncr.31328","volume":"124","author":"IB Greenwell","year":"2018","unstructured":"Greenwell IB, Staton AD, Lee MJ, Switchenko JM, Saxe DF, Maly JJ et al (2018) Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer 124(11):2306\u20132315. https:\/\/doi.org\/10.1002\/cncr.31328","journal-title":"Cancer"},{"issue":"45","key":"5597_CR22","doi-asserted-by":"publisher","first-page":"18250","DOI":"10.1073\/pnas.1314608110","volume":"110","author":"S Be\u00e0","year":"2013","unstructured":"Be\u00e0 S, Vald\u00e9s-Mas R, Navarro A, Salaverria I, Mart\u00edn-Garcia D, Jares P et al (2013) Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 110(45):18250\u201318255. https:\/\/doi.org\/10.1073\/pnas.1314608110","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"5597_CR23","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/bjh.15567","volume":"183","author":"P Jain","year":"2018","unstructured":"Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L et al (2018) Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol 183(4):578\u2013587. https:\/\/doi.org\/10.1111\/bjh.15567","journal-title":"Br J Haematol"},{"issue":"16","key":"5597_CR24","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1182\/blood-2013-01-478834","volume":"121","author":"B Meissner","year":"2013","unstructured":"Meissner B, Kridel R, Lim RS, Rogic S, Tse K, Scott DW et al (2013) The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood 121(16):3161\u20133164. https:\/\/doi.org\/10.1182\/blood-2013-01-478834","journal-title":"Blood"},{"issue":"12","key":"5597_CR25","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1182\/blood.2020005289","volume":"136","author":"F Nadeu","year":"2020","unstructured":"Nadeu F, Martin-Garcia D, Clot G, D\u00edaz-Navarro A, Duran-Ferrer M, Navarro A et al (2020) Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood 136(12):1419\u20131432. https:\/\/doi.org\/10.1182\/blood.2020005289","journal-title":"Blood"},{"issue":"8","key":"5597_CR26","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/gcc.22849","volume":"59","author":"L Streich","year":"2020","unstructured":"Streich L, Sukhanova M, Lu X, Chen YH, Venkataraman G, Mathews S et al (2020) Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A\/B loss, and TP53 mutations: a multi-institutional study. Genes Chromosomes Cancer 59(8):484\u2013494. https:\/\/doi.org\/10.1002\/gcc.22849","journal-title":"Genes Chromosomes Cancer"},{"issue":"6","key":"5597_CR27","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/ajh.25796","volume":"95","author":"S Zhao","year":"2020","unstructured":"Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K (2020) Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623\u2013629. https:\/\/doi.org\/10.1002\/ajh.25796","journal-title":"Am J Hematol"},{"issue":"1","key":"5597_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","volume":"25","author":"R Agarwal","year":"2019","unstructured":"Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE et al (2019) Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med 25(1):119\u2013129. https:\/\/doi.org\/10.1038\/s41591-018-0243-z","journal-title":"Nat Med"},{"key":"5597_CR29","doi-asserted-by":"publisher","first-page":"591577","DOI":"10.3389\/fonc.2020.591577","volume":"10","author":"L Ondrisova","year":"2020","unstructured":"Ondrisova L, Mraz M (2020) Genetic and non-genetic mechanisms of resistance to BCR signaling inhibitors in B cell malignancies. Front Oncol 10:591577. https:\/\/doi.org\/10.3389\/fonc.2020.591577","journal-title":"Front Oncol"},{"issue":"6","key":"5597_CR30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","volume":"34","author":"Z Li","year":"2018","unstructured":"Li Z, Razavi P, Li Q, Toy W, Liu B, Ping C et al (2018) Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the hippo pathway. Cancer Cell 34(6):893-905.e8. https:\/\/doi.org\/10.1016\/j.ccell.2018.11.006","journal-title":"Cancer Cell"},{"issue":"17","key":"5597_CR31","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1158\/0008-5472.can-20-3659","volume":"81","author":"Z Chen","year":"2021","unstructured":"Chen Z, Zhang C, Chen J, Wang D, Tu J, Van Waes C et al (2021) The proteomic landscape of growth factor signaling networks associated with FAT1 mutations in head and neck cancers. Cancer Res 81(17):4402\u20134416. https:\/\/doi.org\/10.1158\/0008-5472.can-20-3659","journal-title":"Cancer Res"},{"issue":"7842","key":"5597_CR32","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s41586-020-03046-1","volume":"589","author":"I Pastushenko","year":"2021","unstructured":"Pastushenko I, Mauri F, Song Y, de Cock F, Meeusen B, Swedlund B et al (2021) Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis. Nature 589(7842):448\u2013455. https:\/\/doi.org\/10.1038\/s41586-020-03046-1","journal-title":"Nature"},{"issue":"4","key":"5597_CR33","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/blood-2018-03-838136","volume":"132","author":"G Clot","year":"2018","unstructured":"Clot G, Jares P, Gin\u00e9 E, Navarro A, Royo C, Pinyol M et al (2018) A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood 132(4):413\u2013422. https:\/\/doi.org\/10.1182\/blood-2018-03-838136","journal-title":"Blood"},{"issue":"23","key":"5597_CR34","doi-asserted-by":"publisher","first-page":"9435","DOI":"10.1073\/pnas.0900571106","volume":"106","author":"S Veeriah","year":"2009","unstructured":"Veeriah S, Brennan C, Meng S, Singh B, Fagin JA, Solit DB et al (2009) The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A 106(23):9435\u20139440. https:\/\/doi.org\/10.1073\/pnas.0900571106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5597_CR35","doi-asserted-by":"publisher","unstructured":"Klintman J, Appleby N, Stamatopoulos B, Ridout K, Eyre TA, Robbe P, Pascua LL, Knight SJL, Dreau H, Cabes M, Popitsch N, Ehinger M, Mart\u00edn-Subero JI, Campo E, M\u00e5nsson R, Rossi D, Taylor JC, Vavoulis DV, Schuh A\u00a0(2021) Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia. Blood 137(20):2800\u20132816. https:\/\/doi.org\/10.1182\/blood.2020005650","DOI":"10.1182\/blood.2020005650"},{"issue":"6","key":"5597_CR36","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3324\/haematol.2018.209015","volume":"104","author":"JF Seymour","year":"2019","unstructured":"Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A et al (2019) Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica 104(6):1202\u20131208. https:\/\/doi.org\/10.3324\/haematol.2018.209015","journal-title":"Haematologica"},{"issue":"23","key":"5597_CR37","doi-asserted-by":"publisher","first-page":"5179","DOI":"10.1182\/bloodadvances.2021004765","volume":"5","author":"DA Bond","year":"2021","unstructured":"Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS et al (2021) Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv 5(23):5179\u20135189. https:\/\/doi.org\/10.1182\/bloodadvances.2021004765","journal-title":"Blood Adv"},{"issue":"5","key":"5597_CR38","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1111\/bjh.15643","volume":"185","author":"C Visco","year":"2019","unstructured":"Visco C, Tisi MC, Evangelista A, Di Rocco A, Zoellner AK, Zilioli VR et al (2019) Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death. Br J Haematol 185(5):940\u2013944. https:\/\/doi.org\/10.1111\/bjh.15643","journal-title":"Br J Haematol"},{"issue":"3","key":"5597_CR39","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjh.14241","volume":"175","author":"CW Eskelund","year":"2016","unstructured":"Eskelund CW, Kolstad A, Jerkeman M, R\u00e4ty R, Laurell A, Eloranta S et al (2016) 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol 175(3):410\u2013418. https:\/\/doi.org\/10.1111\/bjh.14241","journal-title":"Br J Haematol"},{"issue":"26","key":"5597_CR40","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","volume":"386","author":"ML Wang","year":"2022","unstructured":"Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D et al (2022) Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 386(26):2482\u20132494. https:\/\/doi.org\/10.1056\/NEJMoa2201817","journal-title":"N Engl J Med"},{"issue":"3","key":"5597_CR41","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/s1470-2045(21)00638-0","volume":"23","author":"ML Wang","year":"2022","unstructured":"Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L et al (2022) Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (\u226465 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol 23(3):406\u2013415. https:\/\/doi.org\/10.1016\/s1470-2045(21)00638-0","journal-title":"Lancet Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05597-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05597-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05597-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T16:03:17Z","timestamp":1720108997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05597-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,2]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["5597"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05597-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,2]]},"assertion":[{"value":"31 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving patients were reviewed and approved by the Ethics Committee of Peking University Third Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}